Chemistry:Mepartricin
 | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| ATC code | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C60H88N2O19 |
| Molar mass | 1141.359 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Mepartricin is a macrolide polyene compound that is useful for urethra, prostate, and bladder function. It has been studied for use in treating chronic pelvic pain syndrome and benign prostatic hyperplasia.[1][2]
Pharmacodynamics
Mepartricin is an estrogen reabsorption inhibitor that may interfere with the reabsorption of estrogens in the gut leading to increased fecal estrogen excretion. It reduces 17β-estradiol concentration in enterohepatic circulation and decreases estrogen levels in the prostate. The effect of mepartricin on the reabsorption of estrogens was evaluated in studies in vitro and in vivo.
Mepartricin significantly improves pelvic pain and quality of life compared with the results in placebo group after two months of treatment.[1] Regarding to the theory that hormonal disorders could promote prostatic inflammation,[3] mepartricin, that can lower estrogen levels in prostate, is an effective drug in the treatment of patients with chronic pelvic pain syndrome [4] and is referred in 2015 World Journal Pharmacology Updates on therapies for chronic prostatitis/chronic pelvic pain syndrome.
References
- ↑ 1.0 1.1 "Role of mepartricin in category III chronic nonbacterial prostatitis/chronic pelvic pain syndrome: a randomized prospective placebo-controlled trial". Urology 63 (1): 13–6. January 2004. doi:10.1016/j.urology.2003.08.006. PMID 14751338.
- ↑ "Chronic prostatitis". Clin Evid (Online) 2008. 2008. PMID 19450305.
- ↑ "Increased chromogranin A and neuron-specific enolase in rats with chronic nonbacterial prostatitis induced by 17-beta estradiol combined with castration". Int J Clin Exp Pathol 7 (7): 3992–9. 2014. PMID 25120776.
- ↑ "Therapeutic Intervention for Chronic Prostatitis/Chronic Pelvic Pain Syndrome (CP/ CPPS): A Systematic Review and Meta-Analysis". PLOS ONE 7 (8): e41941. 2012. doi:10.1371/journal.pone.0041941. PMID 22870266. Bibcode: 2012PLoSO...741941C.
{{Navbox
| name = Drugs used in benign prostatic hypertrophy | title = Drugs used in [[Medicine:Benign prostatic hyperpbenign prostatic hyperplasia (G04C) | state = collapsed | listclass = hlist
| group1 = 5α-Reductase inhibitors | list1 =
| group2 = Alpha-1 blockers | list2 =
| group3 = Steroidal antiandrogens | list3 =
| group4 = Herbal products | list4 =
| group5 = Others | list5 =
}}
 |  |
